<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>AMR response: John Innes Centre, Norwich</title></head><body><div><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">John Innes Centre, Norwic</span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">h</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (AMR0030)</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Summary</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Coordinated action and funding is needed to enable researchers to work closely with industry and provide a catalyst to progress new candidate molecules through to commercialization.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Establishing </span><span style="font-family:'Times New Roman'; font-size:11pt">centres</span><span style="font-family:'Times New Roman'; font-size:11pt"> of excellence in antimicrobial research will help to combine the expertise required with industry collaboration</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Screening and chemistry platforms are essential</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Mechanisms to ensure industry buy-in could help reverse the slowed rate of antibiotic discovery</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Training for the next generation of synthetic chemists will help ensure the UK can continue to provide leadership in research excellence in this area</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Clarity is needed on how the new research and investment required will be funded</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Introduction to JIC</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Based on the Norwich Research Park (NRP), the John Innes Centre (JIC) forms part of a centre of excellence for research in microbiology in the UK with over 30 groups involved in this critical area of science. NRP’s expertise encompasses a spectrum of activities that includes medical microbiology, anti-microbial resistance and antibiotic discovery, and the </span><a href="http://www.micron.ac.uk/index.htm"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">NRP microbiology community</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> includes commercial entities dedicated to the field of antibiotic discovery, including </span><a href="http://www.procartabio.com/company.php"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Procarta</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline"> </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Biosystems</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><a href="http://www.inspiralis.com/go/about_us.php"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Inspiralis</span></a><span style="font-family:'Times New Roman'; font-size:11pt">. Moreover, the </span><a href="http://www.norwichresearchpark.com/businessandaccommodation/bioincubator/bioincubatorhome.aspx"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Norwich </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Bioincubator</span></a><span style="font-family:'Times New Roman'; font-size:11pt"> was the original home of </span><a href="http://www.novactabio.com/index.php"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Novacta</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline"> </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Biosystems</span></a><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">, a spin-out company from JIC</span><span style="font-family:'Times New Roman'; font-size:11pt"> whose clinical candidate NVB302 for the treatment of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Clostridium </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections recently successfully completed Phase I clinical trials.</span></li></ol><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Recognizing the relevance and potential of NRP science to the area of antimicrobial resistance, we have an active dialogue underway between the interested research groups in order to identify a coordinated action plan for how best our science can be harnessed to address this alarming public health threat.</span></li></ol><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 1: How has anti-microbial resistance developed in the last decade?</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Anti-microbial resistance has been a serious problem for more than a decade and is an inevitable consequence of the use of antibiotics, particularly when used as single therapies.  In recent years there have been some successes with reductions in hospital-borne MRSA and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Clostridium </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">difficile</span><span style="font-family:'Times New Roman'; font-size:11pt"> infections, but this has been described as analogous to ‘squeezing the balloon’, i.e. infections caused by other organisms (e.g. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Neisseria</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">gonorrhoeae</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">carbapenem</span><span style="font-family:'Times New Roman'; font-size:11pt">-resistant </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Enterobacteriaceae</span><span style="font-family:'Times New Roman'; font-size:11pt">) have become problematic. </span><span style="font-family:'Times New Roman'; font-size:11pt">However, no amount of improved hygiene measures can solve the fundamental issue of an increasing burden of antibiotic-resistant bacterial infections and the lack of new drugs to tackle them.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:Calibri; font-size:11pt">Several factors have contributed to the resistance problem over the years:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Overuse of antibiotics; excessive use when not necessary</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Inappropriate use, e.g. for viral infections, or for the wrong bacterial infection – patient pressure/lack of education</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Increased international travel – promotes spread of resistant bacteria (e.g. NDM-1)</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Medical tourism – patients bring back infections to home country</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Lack of new agents – disincentives for </span><span style="font-family:'Times New Roman'; font-size:11pt">Pharma</span><span style="font-family:'Times New Roman'; font-size:11pt"> to engage in antibacterial drug discovery means there are dwindling alternatives</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A dearth of diagnostics - when first prescribing, a physician does not know the type of organism involved and its likely susceptibility to particular antibiotics, leading to inappropriate use and the unnecessary development of resistance in the human flora</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 2: What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Gaps in our knowledge include:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Lack of surveillance, even in the developed world</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Complete lack of knowledge about resistance issues in some countries</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Mis</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">-reporting of deaths due to AMR</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Detailed knowledge of the origin of many antibiotic resistant pathogens (e.g. relative contributions of agricultural and human use of antibiotics) </span></li></ul><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 3:  Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection?  If not, how could this be rectified?</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">No.  We need more coordinated action, e.g.</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Establishment of centres of therapeutic excellence (in UK or EU) with government investment and industrial input. The focus needs to be new molecule discovery, development of orphan compounds by chemists, research on drug targets, screening candidates against pathogens, research to understand how resistance develops, and collaboration with industry to progress the results of research through to commercialisation. A centre will need to combine excellence in synthetic chemistry and biosynthesis as well as in microbial research.</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Funding for collaboration between publically funded scientists and contract research organisations for pre-clinical candidate drug discovery. There is a gap between molecule discovery and the development of candidates through to Phase 1b proof-of-concept studies.</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Consideration of ‘not for profit’ models</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Co-development of diagnostics is essential – currently this issue makes it very difficult to stratify patients for clinical trial design</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Increase development of broad spectrum anti-virulence treatments</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Training for the next generation of chemists who will be required to help drive discovery</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">EU initiatives like </span><a href="http://www.imi.europa.eu/content/combacte"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; font-weight:normal; text-decoration:underline">IMI</span></a></li></ul><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">What will the process look like?</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Phenotypic (whole cell screening) and appropriate chemistry platforms are critical</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Natural product-based compounds still account for more than half of recent approvals and new classes; huge advances have been made in natural products science over the last 15 years that allow streamlining of their inclusion in the discovery process.</span></li></ul><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 4: What measures (including </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">behavioural</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">For HIV: the acceptance of safe sex measures is one example of behavioural change; also, the development of combination HAART therapy including single fixed dose combination ‘pills’ which improve compliance. </span></li></ol><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">For HCV: as with HIV the efficacy of combination therapy targeting multiple mechanisms and with the inclusion of an agent having a high barrier to resistance can overcome selection of resistant organisms. Moreover, the regulatory agencies have been open to innovative clinical plans including combining multiple trial agents at Phase 2.</span></li></ol><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">With AMR, measures could include:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Altering patients’ expectations about receiving antibiotics, i.e. prescribe only when necessary</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Ensure that GPs prescribe antibiotics only when strictly necessary</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Persuade the general public to get into the hand-washing/hygiene routine in many walks of life, not just in hospitals</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Persuade people, in all countries, that the practice of providing antibiotics ‘over the counter’ is unacceptable</span></li></ul><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 5: What global coordination and agreement is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Initatives</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> need to include:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt; vertical-align:-1pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Stricter controls on non-human use</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt; vertical-align:-1pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Limitations on ‘over the counter’ availability</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt; vertical-align:-1pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Uniform prescribing policies</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt; vertical-align:-1pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Realisation of the problem at the level of governments leading to coordinated action</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt; vertical-align:-1pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Incentives in tax/patents/pricing to increase willingness of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Pharma</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> to engage and share experiences</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt; vertical-align:-1pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Rationalisation of the regulatory environment – drug developers are shackled, especially for new mechanisms or combinations</span></li></ul><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Question 6: What are the strengths and weaknesses of the Government's 2013-2018 strategy for tackling antimicrobial resistance?  What changes might be made to further strengthen the Government's action plan? </span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Strengths:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Appropriate recognition and articulation of the problem</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Breaking down of the problem into its component issues</span></li></ul><p style="margin:0pt 0pt 0pt 54pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Weaknesses:</span></li></ol><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt; vertical-align:-1pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Too heavily focussed on identifying problems and insufficiently focussed on solutions</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt; vertical-align:-1pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">No clarity on how work going forward will be funded, e.g. MRC, NHS, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Wellcome</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal"> Trust, BBSRC, TSB.</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Leadership not identified</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">Needs clarity on how investment by industry will be de-risked</span></li><li style="font-family:Symbol; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">It requires mechanisms to ensure industry buy-in so that new discoveries can be taken forward and enter the market place.</span></li></ul><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 54pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:normal">November 2013</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p></div></body></html>